Meridian Bioscience Gets FDA Re-authorization Of EUA For Revogene SARS-CoV-2 Molecular Assay
(RTTNews) - Diagnostic testing provider Meridian Bioscience, Inc. (VIVO) announced Friday that it received re-authorization of its Emergency Use Authorization (EUA) for the Revogene SARS-COV-2 molecular assay from the U.S. Food and Drug Administration (FDA).
Meridian expects to begin shipping this product before the end of its fiscal fourth quarter, ending September 30, 2022.
On November 10, 2021, Meridian announced the Revogene SARS-CoV-2 assay was granted authorization by the FDA. Subsequent to that, it was determined that the original design of the assay would not detect the Omicron variant.
Over the last few months in consultation with the FDA, Meridian completed additional clinical studies and the FDA has now re-authorized the EUA.
For More Such Health News, visit rttnews.com
read more
European Economic News Preview: Germany Industrial Output, Trade Data Due
Industrial production and foreign trade from Germany and retail sales from the euro area are the top economic news due on Thursday. At 2.00 am ET, Destatis is slated to issue Germany's industrial output and trade figures. Exports are expected to rebound 2.0 percent on month in November and imports to climb 0.7 percent.
RTTNews
|
6h 7min ago
China Inflation Eases To 0.1%; PPI Continues To Drop
China's consumer price inflation softened further in December and producer prices declined for 27 consecutive months despite Beijing initiating stimulus measures to revive domestic demand. Consumer prices grew only 0.1 percent on a yearly basis in December, slower than the 0.2 percent increase seen in November, figures from the National Bureau of Statistics revealed on Thursday.
RTTNews
|
6h 14min ago
European Shares May Struggle To Find Footing Amid Economic Uncertainty
European stocks may struggle for direction on Thursday, with trading volumes likely to remain thin due to a holiday in the U.S. to honor the death of former President Jimmy Carter.
RTTNews
|
7h 33min ago
Sensex, Nifty Open Lower On Weak Global Cues
Indian shares were subdued on Thursday, tracking weak cues from global markets as Chinese inflation data disappointed and reports suggested that U.S. President-elect Donald Trump was mulling a national economic emergency declaration to provide legal justification for a series of universal tariffs on allies and adversaries.
RTTNews
|
8h 27min ago
Asian Markets Mostly Lower
Asian stock markets are trading mostly lower on Thursday, following the mixed cues from Wall Street overnight, amid uncertainty about the outlook for interest rates following mixed U.S. jobs data. The minutes of the US Fed's latest monetary policy meeting also did not provide much insight into interest rates other than to suggest officials plan to take a "careful approach" to future decisions.
RTTNews
|
9h 40min ago
Australian Market Slightly Trims Early Losses In Mid-market
The Australian market slightly trimmed the early losses and is trading notably lower in mid-market moves on Thursday. The benchmark S&P/ASX 200 is falling to near the 8,300 level, with weakness across most sectors led by technology and financial stocks. Gold miners remain the only bright spot.
RTTNews
|
10h 19min ago
Sensex, Nifty Likely To Open On Cautious Note
Indian shares are seen opening on a cautious note Thursday as investors await cues from the upcoming Q3 earnings season and prepare for the highly anticipated U.S. jobs report due on Friday that could shed more light on the Federal Reserve's policy outlook.
RTTNews
|
10h 31min ago
Thai Shares May Tick Higher On Thursday
The Thai stock market has alternated between positive and negative finishes through the last four trading days since the end of the two-day slide in which it had slumped more than 20 points or 1.5 percent. The Stock Exchange of Thailand now sits just beneath the 1,390-point plateau and they're expected to open slightly to the upside on Thursday.
RTTNews
|
11h 2min ago
